We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 11-20 of 1,448

Ongoing Infringement Must be Parsed to Determine Relevant Limitation Periods
  • Bereskin & Parr LLP
  • Canada
  • January 24 2017

In the recent decision of Apotex Inc v AstraZeneca Canada Inc 2017 FCA 9 relating to the drug omeprazole, the Federal Court of Appeal held that in

Biosimilars in Canada: at a tipping point
  • Osler Hoskin & Harcourt LLP
  • Canada
  • May 24 2016

Biosimilars, or highly similar versions of innovative biologic medicines, have now been approved and marketed in developed countries for several

Patenting Polymorphs of Crystals Internationally
  • Bereskin & Parr LLP
  • Canada, European Union, Japan, USA
  • June 27 2016

Polymorphs are patentable subject matter in Canada and the U.S. Our prior article discussed some best practices to differentiate a new polymorph from

Obviousness central to Federal Court’s REYATAZ (atazanavir bisulfate) decision
  • Gowling WLG
  • Canada
  • June 24 2016

In a decision dated May 27, 2016 in respect of Bristol-Myers Squibb’s (“BMS”) REYATAZ (atazanavir bisulfate), Justice Mactavish of the Federal

The TPP new rights for pharmaceutical patent holders in Canada
  • Gowling WLG
  • Canada
  • November 13 2015

The Canadian Government released the official consolidated text of the Trans-Pacific Partnership (TPP) agreement on Nov., 5, 2015. This follows the

Prohibition order denied against Apotex for generic tenofovir disoproxilemtricitabine
  • Smart & Biggar/Fetherstonhaugh
  • Canada
  • October 31 2016

The Federal Court dismissed Gilead's prohibition application against Apotex for its tenofovir disoproxil fumarate (TDF) and emtricitabine fixed dose

Teva v Pfizer, or the “Viagra saga”: if there is no quid proper disclosure there can be no quo exclusive monopoly rights
  • Fasken Martineau DuMoulin LLP
  • Canada
  • November 19 2012

Sildenafil is the active ingredient in Viagra, the blockbuster potency-enhancing drug marketed by Pfizer

Celgene Corp. v. Canada (Attorney General)
  • WeirFoulds LLP
  • Canada
  • February 16 2011

In this case, the Supreme Court of Canada upheld a regulatory board's decision to interpret its statutory mandate with reliance on a consumer protection purpose

Court grants motion to reopen trial and admit new evidence
  • Borden Ladner Gervais LLP
  • Canada
  • April 27 2011

The Federal Court granted leave to reopen the trial and admit new evidence in a matter under reserve, in which no reasons or judgement have issued

Federal Court declares omeprazole formulation patent valid and infringed
  • Norton Rose Fulbright Canada LLP
  • Canada
  • March 25 2015

On March 16, 2015, Justice Barnes of the Federal Court issued his decision in AstraZeneca Canada Inc. et al v. Apotex Inc., 2015 FC 322, declaring